Plasma (Octaplas LG) - Octapharma

Drug Profile

Plasma (Octaplas LG) - Octapharma

Alternative Names: Octaplas (US) - Octapharma; Octaplas LG; OctaplasLG; Plasma (OctaplasLG) - Octapharma

Latest Information Update: 22 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Octapharma
  • Class Blood products and substitutes
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blood coagulation disorders; Haemorrhage; Thrombotic thrombocytopenic purpura
  • Phase II Septic shock

Most Recent Events

  • 18 Apr 2017 Phase-II clinical trials in Septic shock in Denmark (IV) (NCT03092245)
  • 27 Feb 2012 Preregistration for Haemorrhage in USA (IV)
  • 27 Feb 2012 Preregistration for Coagulation disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top